Company intelligence / Profile preview

Sabz Biomedicals

Ownership: Private
Development stage: Other

Overview

Sabz Biomedicals has established protocols for the development and expansion of CD19-targeted CAR T cells. Their work demonstrates successful activation, expansion, and transduction of T cells with lentiviral vectors encoding anti-CD19 chimeric antigen receptors. This represents an important step toward enabling preclinical and future clinical studies for cancer immunotherapy in resource-limited settings.[5] There are no published clinical trial results yet.

Therapeutic areas: OtherOncology
Modalities: CAR-T cell therapyCell therapyLaboratory supplies (supporting research)Professional software (supporting research)
Industry: Biotech

Beyond the preview

Go deeper on Sabz Biomedicals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sabz Biomedicals.

Explore the full profile